Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 1/20 | 0.37 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.37 |
| ▸ | ESR2 | Q92731 | 4/20 | 0.36 |
| ▸ | DRD2 | P14416 | 1/20 | 0.35 |
| ▸ | DRD4 | P21917 | 1/20 | 0.35 |
| ▸ | ESR1 | P03372 | 3/20 | 0.33 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.33 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.33 |
| ▸ | HTR1A | P08908 | 1/20 | 0.32 |
| ▸ | HTR1D | P28221 | 1/20 | 0.32 |
| ▸ | HTR2C | P28335 | 1/20 | 0.32 |
| ▸ | HTR2A | P28223 | 1/20 | 0.32 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14234588 | 0.81 | EGFR (0.35) | CHRNB2CHRNA4ESR2ESR1 | |
| SCHEMBL5493492 | 0.81 | TACR2 (0.39) | CHRNB2CHRNA4SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL14724849 | 0.81 | CHRNB2 (0.37) | CHRNB2CHRNA4SLC6A2SLC6A4HTR1A | |
| SCHEMBL19187434 | 0.80 | ADRA2A (0.38) | HTR1AHTR1DHTR2C | |
| SCHEMBL13579980 | 0.80 | MEN1 (0.42) | CHRNB2CHRNA4ESR2DRD2DRD4 | |
| SCHEMBL27858124 | 0.79 | HTR2A (0.39) | HTR2A | |
| SCHEMBL12369307 | 0.77 | CHRNB2 (0.37) | CHRNB2CHRNA4ESR2DRD2DRD4 | |
| SCHEMBL7448411 | 0.77 | HTR2A (0.39) | HTR2CHTR2A | |
| SCHEMBL11473137 | 0.76 | IDO1 (0.45) | HTR2A | |
| SCHEMBL29558888 | 0.76 | IDO1 (0.45) | HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8507528-B2 | 2-alkyl-indazole compounds for the treatment of certain cns-related disorders | AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.P.A. (IT) | 2013-08-13 | — | — | US | disclosed |
| CN-101558057-B | 2 -alkyl- indazole compounds for the treatment of certain cns-related disorders | ACRAF | 2013-05-01 | — | — | CN | disclosed |
| EP-2099780-B1 | 2 -ALKYL- INDAZOLE COMPOUNDS FOR THE TREATMENT OF CERTAIN CNS-RELATED DISORDERS | ACRAF (IT) | 2013-01-09 | — | — | EP | disclosed |
| WO-2012163898-A1 | DYE COMPOSITION USING A (HYDROXY)INDOLINE COUPLER IN A MEDIUM RICH IN FATTY SUBSTANCES, PROCESS AND DEVICES | L'OREAL (FR) | 2012-12-06 | — | — | WO | disclosed |
| US-20100056573-A1 | 2-ALKYL-INDAZOLE COMPOUNDS FOR THE TREATMENT OF CERTAIN CNS-RELATED DISORDERS | AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.P.A. (IT) | 2010-03-04 | — | — | US | disclosed |
| CN-101558057-A | 2 -alkyl- indazole compounds for the treatment of certain cns-related disorders | ACRAF (IT) | 2009-10-14 | — | — | CN | disclosed |
| EP-2099780-A1 | 2 -ALKYL- INDAZOLE COMPOUNDS FOR THE TREATMENT OF CERTAIN CNS-RELATED DISORDERS | AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.p.A. (IT) | 2009-09-16 | — | — | EP | disclosed |
| WO-2008061688-A1 | 2 -ALKYL- INDAZOLE COMPOUNDS FOR THE TREATMENT OF CERTAIN CNS-RELATED DISORDERS | AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.P.A. (IT) | 2008-05-29 | — | — | WO | disclosed |
| US-20070129312-A1 | Convalent conjugates of biologically-active compounds with amino acids and amino acid derivatives for targeting to physiologically-protected sites | YATVIN MILTON B | 2007-06-07 | — | — | US | disclosed |
| US-20070129312-A1 | Convalent conjugates of biologically-active compounds with amino acids and amino acid derivatives for targeting to physiologically-protected sites | YATVIN MILTON B | 2007-06-07 | — | — | US | disclosed |
| CN-1282644-C | Indane or indoline derivative | LUNDBECK & CO AS H (DK) | 2006-11-01 | — | — | CN | disclosed |
| CN-1267438-C | antidepressant indoletetrahydropyridine derivatives of 2,3-dihydro-7h-[1,4] dioxino [2,3-3] indole | WYETH CORP (US) | 2006-08-02 | — | — | CN | disclosed |
| CN-1244558-C | 1,2-indane or indoline derivative | LUNDBECK & CO AS H (DK) | 2006-03-08 | — | — | CN | disclosed |
| CN-1515551-A | 1,2-indane or indoline derivative | H.¡�±�������˾ | 2004-07-28 | — | — | CN | disclosed |
| CN-1503800-A | antidepressant indoletetrahydropyridine derivatives of 2,3-dihydro-7h-[1,4] dioxino [2,3-3] indole | — | 2004-06-09 | — | — | CN | disclosed |
| CN-1495165-A | Indane or indoline derivative | H.¡�±�������˾ | 2004-05-12 | — | — | CN | disclosed |
| CN-1146556-C | 1, 2-indane or indoline derivative and preparation method and application thereof | H.¡�±�������˾ | 2004-04-21 | — | — | CN | disclosed |
| CN-1246117-A | 1, 2-indane or indoline derivatives | LUNDBECK & CO AS H (DK) | 2000-03-01 | — | — | CN | disclosed |
| CN-1036566-A | 1,3,4,5-tetrahydro benzo [c, d] diindyl compounds | BAYER AG (DE) | 1989-10-25 | — | — | CN | disclosed |
| CN-87107539-A | The alkaline 2-amino-1,2,3,4-tetralin that replaces | — | 1988-07-13 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100056573-A1 | 2-ALKYL-INDAZOLE COMPOUNDS FOR THE TREATMENT OF CERTAIN CNS-RELATED DISORDERS | CYP11B2, CYP1A2, INA | CHRNB2 85/4885CHRNA4 146/4885ESR2 2686/4885 |
| US-20070129312-A1 | Convalent conjugates of biologically-active compounds with amino acids and amino acid derivatives for targeting to physiologically-protected sites | SLC7A1, SLC1A1, DNPEP | CHRNB2 1459/4885CHRNA4 959/4885ESR2 4568/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.